EViSCO Trial

Trial Acronym EViSCO
Clinical Area Respiratory
Description Epstein-Barr Virus Suppression in Chronic Obstructive Pulmonary Disease
Status Analysis and Reporting
RECRUITMENT
Target Recruitment 88
Recruitment to date 85 as of 31/03/2020 (recruitment closed)
TRIAL DESIGN
Trial Design Randomised double-blind, placebo-controlled trial of 1 gram three times daily of valaciclovir or placebo for 8 weeks in COPD patients with Epstein-Barr virus
Study Aim To establish if an antiviral therapy (valaciclovir) used to treat other herpes viruses is safe in patients with COPD and to examine whether it is possible to supress EBV in the airways of patients with COPD and examine important outcome measures including lung function and markers of airway inflammation in the blood and sputum.
CHIEF INVESTIGATOR (CI)
Chief Investigator Dr Joe Kidney
SPONSOR(s) & FUNDER(s)
Sponsors Belfast Health and Social Care Trust
Funder Mater YP Trustees